Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
Prostate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a...
Main Authors: | Jonas S. Heitmann, Martin Pfluegler, Gundram Jung, Helmut R. Salih |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/3/549 |
Similar Items
-
An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2021-02-01) -
Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01) -
Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01) -
CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
by: Joseph Kauer, et al.
Published: (2021-09-01) -
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01)